Induced urinary crystal formation as an analytical strategy for the prediction and monitoring of urolithiasis and other metabolism-related disorders
详细信息 查看全文
- 作者：Norbert Laube (1) (2)
Wolfgang Berg (3)
Falk Bernsmann (2)
Sascha Gravius (4)
Florian Klein (5)
Stefan Latz (6)
Dirk von Mallek (7)
Tadeusz Porowski (8)
Thomas Randau (4)
Anna Wasilewska (8)
Christian Fisang (6)
1. Deutsches Harnsteinzentrum ; Urologisches Zentrum Bonn Friedensplatz ; Friedensplatz 16 ; Bonn ; 53111 ; Germany
2. NTTF Coatings GmbH ; Maarweg 32 ; Rheinbreitbach ; 53619 ; Germany
3. Clinic and Policlinic of Urology ; Friedrich Schiller University of Jena ; Lessingstra脽e 1 ; Jena ; 07743 ; Germany
4. Clinic for Orthopaedics and Trauma Surgery ; Friedrich-Wilhelms-Universit盲t Bonn ; Sigmund-Freud-Stra脽e 25 ; Bonn ; 53127 ; Germany
5. FH Aachen ; Campus J眉lich ; FB Medizintechnik und Technomathematik ; Heinrich-Mu脽mann-Stra脽e 1 ; J眉lich ; 52428 ; Germany
6. Clinic and Policlinic of Urology and Pediatric Urology ; Friedrich-Wilhelms-Universit盲t Bonn ; Sigmund-Freud-Stra脽e 25 ; Bonn ; 53127 ; Germany
7. Department of Research ; Federal Institute for Drugs and Medical Devices (BfArM) ; Kurt-Georg-Kiesinger-Allee 3 ; Bonn ; 53175 ; Germany
8. Department of Pediatrics and Nephrology ; Medical University of Bia艂ystok ul ; Waszyngtona 17 ; Bia艂ystok ; 15-546 ; Poland - 关键词：Urinary crystal formation ; Metabolic diseases ; Disease/treatment monitoring ; Predictive preventive personalised medicine ; Bonn ; Risk ; Index ; Nephropathies ; Meno ; /andropause
- 刊名：The EPMA Journal
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：5
- 期：1
- 全文大小：2,398 KB
- 参考文献：1. International Union of Pure and Applied Chemistry (IUPAC): Compendium of Chemical Terminology, Gold Book. 2012. Version 2.3.2, 2012鈥?8鈥?9. [http://goldbook.iupac.org/PDF/goldbook.pdf]
Ion Association. Butterworths, London, UK
2. Merkel, BJ, Planer-Friedrich, B (2008) Groundwater Geochemistry: a Practical Guide to Modeling of Natural and Contaminated Aquatic Systems. Springer-Verlag, Berlin-Heidelberg, Germany
3. Jewett, JR, Jensen, L (2000) Assessment of Available Particle Size Data to Support an Analysis of the Waste Feed Delivery Transfer System. (River Protection Project) RPP-6247, Rev 0. CH2Mhill. Hanford Group, Richland WA CrossRef
4. Amjad, Z (2010) The Science and Technology of Industrial Water Treatment. CRC Press, Taylor & Francis Group, Boca Raton, London, New York CrossRef
5. Anthony JW, Bideaux RA, Bladh KW, Nichols MC: / Handbook of Mineralogy. Chantilly, VA, USA: Mineralogical Society of America; 20151鈥?1110. [ofmineralogy.org/" class="a-plus-plus">http://www.handbookofmineralogy.org/]
6. The New IMA List of Minerals鈥攁 Work in Progress 2013.http://pubsites.uws.edu.au/ima-cnmnc/IMA_Master_List_%282013-08%29.pdf
7. Strunz, H, Nickel, EH (2001) Strunz Mineralogical Tables. Chemical-Structural Mineral Classification System. Schweizerbart, Stuttgart, Germany
8. LeCorre, KS, Valsami-Jones, E, Hobbs, P, Parsons, SA (2005) Impact of calcium on struvite crystal size, shape and purity. J Cryst Growth 283: pp. 514-522 CrossRef
9. Abbona, F, Franchini-Angela, M (1990) Crystallization of calcium and magnesium phosphates from solutions of low concentration. J Cryst Growth 104: pp. 661-671 248(90)90009-A" target="_blank" title="It opens in new window">CrossRef
10. Abbona, F, Lundager Madsen, HE, Boistelle, R (1988) The final phases of calcium and magnesium phosphates precipitated from solutions of high to medium concentration. J Cryst Growth 89: pp. 592-602 248(88)90223-0" target="_blank" title="It opens in new window">CrossRef
11. Lind, BB, Ban, Z, Bayd茅n, S (2000) Nutrient recovery from human urine by struvite crystallization with ammonia adsorption on zeolite and wollastonite. Bioresour Technol 73: pp. 169-174 24(99)90157-8" target="_blank" title="It opens in new window">CrossRef
12. Andrade, A, Schuiling, RD (2001) The chemistry of struvite crystallization. Min J 23: pp. 5-6
13. Blank, R (1996) Beitr盲ge zur Eliminierung und R眉ckgewinnung von Ammoniumstickstoff aus Abwasser. Technische Universit盲t Dresden, Dresden
14. Leitlinien zur Diagnostik: Therapie und Metaphylaxe der Urolithiasis. AWMF-Leitlinien-Register Nr; 2009. 043/025, 02/[http://www.awmf.org/leitlinien/detail/II/043-025.html]
15. Worcester, EM (1994) Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol 5: pp. 46-53
16. Aggarwal, KP, Narula, S, Kakkar, M, Tandon, C (2013) Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. Bio Med Res Int 2013: pp. 1-21 CrossRef
17. Khan, SR, Kok, DJ (2004) Modulators of urinary stone formation. Front Biosci 9: pp. 1450-1482 CrossRef
18. Garti, N, Tibika, F, Sarig, S, Perlberg, S (1980) The inhibitory effect of polymeric carboxylic amino-acids and urine on calcium oxalate crystallization. Biochem Biophys Res Commun 97: pp. 1154-1162 CrossRef
19. Bek-Jensen, H, Fornander, AM, Nilsson, MA, Tiselius, HG (1996) Is citrate an inhibitor of calcium oxalate crystal growth in high concentrations of urine?. Urol Res 24: pp. 67-71 CrossRef
20. Weaver, ML, Qiu, SR, Hoyer, JR, Casey, WH, Nancollas, GH, De Yoreo, JJ (2007) Inhibition of calcium oxalate monohydrate growth by citrate and the effect of the background electrolyte. J Cryst Growth 306: pp. 135-145 CrossRef
21. Wunderlich, W (1981) Aspects of the influence of magnesium ions on the formation of calcium oxalate. Urol Res 9: pp. 157-161 CrossRef
22. Christensen, B, Petersen, TE, S酶rensen, ES (2008) Posttranslational modification and proteolytic processing of urinary osteopontin. Biochem J 411: pp. 53-61 CrossRef
23. Wang, LJ, Zhang, W, Qiu, SR, Zachowicz, WJ, Guan, X, Tang, R, Hoyer, JR, De Yoreo, JJ, Nancollas, GH (2006) Inhibition of calcium oxalate monohydrate crystallization by the combination of citrate and osteopontin. J Cryst Growth 291: pp. 160-165 CrossRef
24. Konya, E, Umekawa, T, Iguchi, M, Kurita, T (2003) The role of osteopontin on calcium oxalate crystal formation. Eur Urol 43: pp. 564-571 CrossRef
25. Gokhale, JA, Glenton, PA, Khan, SR (2001) Characterization of Tamm-Horsfall protein in a rat nephrolithiasis model. J Urol 166: pp. 1492-1497 CrossRef
26. Mo, L, Huang, HY, Zhu, XH, Shapiro, E, Hasty, DL, Wu, XR (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66: pp. 1159-1166 CrossRef
27. Hess, B (1991) The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 5: pp. 689-695
28. Cody, AM, Cody, RD (1994) Calcium oxalate trihydrate phase control by structurally-specific carboxylic acids. J Cryst Growth 135: pp. 235-245 248(94)90746-3" target="_blank" title="It opens in new window">CrossRef
29. DeStefano, C, Gianguzza, A, Piazzese, D, Sammartano, S (2003) Polyacrylates in aqueous solution. The dependence of protonation on molecular weight, ionic medium and ionic strength. React Funct Polymers 55: pp. 9-20 CrossRef
30. Akyol, E, Bozkurt, A, 脰ner, M (2006) The effects of polyelectrolytes on the inhibition and aggregation of calcium oxalate crystallization. Polym Adv Technol 17: pp. 58-65 CrossRef
31. Meyer, JL, Lee, KE, Bergert, JH (1977) The inhibition of calcium oxalate crystal growth by multidentate organic phosphonates. Calcif Tissue Res 23: pp. 83-86 CrossRef
32. S酶rensen, S, Hansen, K, Bak, S, Justesen, SJ (1990) An unidentified macromolecular inhibitory constituent of calcium oxalate crystal growth in human urine. Urol Res 18: pp. 373-379 CrossRef
33. Grases, F, MiDan, A, Sohnel, O (1992) Role of agglomeration in calcium oxalate monohydrate urolith development. Nephron 61: pp. 145-150 CrossRef
34. Chien, YC, Masica, DL, Gray, JJ, Nguyen, S, Vali, H, McKee, MD (2009) Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning. J Biol Chem 284: pp. 23491-23501 CrossRef
35. Grohe, B, Taller, A, Vincent, PL, Tieu, LD, Rogers, KA, Heiss, A, S酶rensen, ES, Mittler, S, Goldberg, HA, Hunter, GK (2009) Crystallization of calcium oxalates is controlled by molecular hydrophilicity and specific polyanion-crystal interactions. Langmuir 25: pp. 11635-11646 CrossRef
36. Sikiri膰, MD, F眉redi-Milhofer, H (2006) The influence of surface active molecules on the crystallization of biominerals in solution. Adv Colloid Interface Sci 128鈥?30: pp. 135-158 CrossRef
37. Fleisch, H, Russel, RG Experimental and clinical studies with polyphosphate and disphosphonates. In: David, DS eds. (1977) Calcium Metabolism in Renal Failure and Nephrolithiasis. Wiley & Sons, New York Chichester, pp. 293-336
38. Ralston, PH (1972) Inhibiting water formed deposits with threshold compositions. Mater Protect Perform 11: pp. 39-44
39. Nancollas, GH, Reddy, MM (1974) The kinetics of crystallization of scale-forming minerals. Soc Petrol Eng J 14: pp. 117-126 CrossRef
40. Nyvlt, J, Ulrich, J (1995) Admixtures in Crystallization. Weinheim, Germany, VCH Verlagsgesellschaft mbH CrossRef
41. Rose, GA (1982) Urinary Stones: Clinical and Laboratory Aspects. MTP Press, Lancaster, UK
42. Kavanagh, JP (2006) In vitro calcium oxalate crystallisation methods. Urol Res 34: pp. 139-145 240-005-0027-z" target="_blank" title="It opens in new window">CrossRef
43. Laube, N, Schneider, A, Hesse, A (2000) A new approach to calculate the risk of calcium oxalate crystallization from unprepared native urine. Urol Res 28: pp. 274-280 2400000124" target="_blank" title="It opens in new window">CrossRef
44. Laube, N, Klein, F, Bernsmann, F, Fisang, C (2014) Neues Harn-Diagnostikverfahren zur individuellen 脺berwachung des Harnsteinrisikos und anderer Stoffwechselerkrankungen. Deutsche Med Wochenschrift 139: pp. 1721-1725 CrossRef
45. Batini膰, D, Milosevi膰, D, Blau, N, Konjevoda, P, Stambuk, N, Barbari膰, V, Subat-Dezulovi膰, M, Votava-Rai膰, A, Nizi膰, L, Vrljicak, K (2000) Value of the urinary stone promoters/inhibitors ratios in the estimation of the risk of urolithiasis. J Chem Inf Comput Sci 40: pp. 607-610 CrossRef
46. Laube, N, Rodgers, A, Allie-Hamdulay, S, Straub, M (2008) Calcium oxalate stone formation risk鈥攁 case of disturbed relative concentrations of urinary components. Clin Chem Lab Med 46: pp. 1134-1139 CrossRef
47. Berg, W, M盲urer, F, Brundig, P, Bothor, C, Schulz, E (1983) Possibilities of computing urine parameters as a means of classification of normals and patients suffering from calcium oxalate lithiasis. Eur Urol 9: pp. 353-358
48. King, JS, O鈥機onnor, FJ, Smith, MJ, Crouse, L (1968) The urinary calcium-magnesium ratio in calcigerous stone formers. Invest Urol 6: pp. 60-65
49. Parks, JH, Coe, FL (1986) A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30: pp. 85-90 CrossRef
50. Tiselius, HG (1983) Different estimates of the risk of calcium oxalate crystallization in urine. Eur Urol 9: pp. 231-234
51. Knoll, T (2010) Epidemiology, pathogenesis and pathophysiology of urolithiasis. Eur Urol Suppl 9: pp. 802-806 CrossRef
52. Tiselius, HG (1982) An improved method for the routine biochemical evaluation of patients with recurrent calcium oxalate stone disease. Clin Chim Acta 122: pp. 409-418 CrossRef
53. Tiselius, HG (1997) Risk formulas in calcium oxalate urolithiasis. World J Urol 15: pp. 176-185 CrossRef
54. Brown, CM, Ackermann, DK, Purich, DL (1994) EQUIL93: a tool for experimental and clinical urolithiasis. Urol Res 22: pp. 119-126 CrossRef
55. Werness, PG, Brown, CM, Smith, LH, Finlayson, B (1985) EQUIL 2: a basic computer program for the calculation of urinary supersaturation. J Urol 134: pp. 1242-1244
56. May, PM, Murray, K (1991) JESS, a joint expert specification system鈥擨. Talanta 38: pp. 1409-1417 CrossRef
57. May, PM, Murray, K (1991) JESS, a joint expert specification system鈥擨I. The thermodynamic database. Talanta 38: pp. 1419-1426 CrossRef
58. Rodgers, A, Allie-Hamdulay, S, Jackson, G (2006) Therapeutic action of citrate in urolithiasis explained by chemical specification: increase in pH is the determinant factor. Nephrol Dial Transplant 21: pp. 361-369 CrossRef
59. Grover, PK, Ryall, RL, Marshall, VR (1990) Does Tamm-Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine?. Clin Chim Acta 190: pp. 223-238 CrossRef
60. Atmani, F, Glenton, PA, Khan, SR (1998) Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol Res 26: pp. 201-207 2400050047" target="_blank" title="It opens in new window">CrossRef
61. Ryall, R (2004) Macromolecules and urolithiasis: parallels and paradoxes. Nephron Physiol 98: pp. 37-42 CrossRef
62. Aihara, K, Byer, KJ, Khan, SR (2003) Calcium phosphate-induced renal epithelial injury and stone formation: involvement of reactive oxygen species. Kidney Int 64: pp. 1283-1291 CrossRef
63. Laube, N, Hergarten, S, Hoppe, B, Schmidt, M, Hesse, A (2004) Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas. J Urol 172: pp. 355-359 CrossRef
64. Laube, N, Kleinen, L Risk indices. In: Rao, NP, Preminger, GM, Kavanagh, JP eds. (2011) Urinary Tract Stone Disease. Springer-Verlag, London, pp. 355-368
65. Lee, S, Oncescu, V, Mancuso, M, Mehta, S, Erickson, D (2014) A smartphone platform for the quantification of vitamin D levels. Lab Chip 21: pp. 1437-1442 CrossRef
66. Oncescu, V, O鈥橠ell, D, Erickson, D (2013) Smartphone based health accessory for colorimetric detection of biomarkers in sweat and saliva. Lab Chip 13: pp. 3232-3238 CrossRef
67. Gerbrandy, J, Hellendoorn, HB (1957) Calciuria as diagnostic criterion in hormonal therapy of metastasizing breast carcinoma. Ned Tijdschr Geneeskd 101: pp. 1257-1263
68. O鈥橬eill, S, Walker, F, O鈥橠wyer, WF (1980) Adeno-carcinoma of the bronchus presenting with bi-hilar adenopathy, Bell鈥檚 palsy and absorptive hypercalciuria. Ir Med J 73: pp. 313-314
69. Seward, GR, Beales, SJ, Jonson, NW, Sita Lumsden, EG (1975) A metastasising ameloblastoma associated with renal calculi and hypercalcaemia. Cancer 36: pp. 2277-2285 CrossRef
70. Chung, SD, Liu, SP, Lin, HC (2013) A population-based study on the association between urinary calculi and kidney cancer. Can Urol Assoc J 7: pp. E716-E721
71. Verma, N, Yadav, G, Dhawan, N, Kumar, A (2011) Squamous cell carcinoma of kidney co-existing with renal calculi: a rare tumour. BMJ Case Reports 2011: pp. 1-3
72. Gawade, PL, Ness, KK, Sharma, S, Li, Z, Srivastava, DK, Spunt, SL, Nottage, K, Krasin, MJ, Hudson, MM, Kaste, SC (2012) Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia. J Cancer Surviv 6: pp. 388-397 241-y" target="_blank" title="It opens in new window">CrossRef
73. Camacho, PM, Dayal, AS, Diaz, JL, Nabhan, FA, Agarwal, M, Norton, JG, Robinson, PA, Albain, KS (2008) Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol 26: pp. 5380-5385 CrossRef
74. Klahr, S, Schreiner, G, Ichikawa, I (1988) The progression of renal disease. N Engl J Med 318: pp. 1657-1666 CrossRef
75. Bianchetti, MG, Oetliker, OH (1990) Calciuria in Bartter鈥檚 syndrome. Scand J Urol Nephrol 24: pp. 239-242 CrossRef
76. Mitome, J, Kawaguchi, Y, Arase, S, Horino, T, Okada, H, Osaka, N, Hanaoka, K, Shimada, T, Kawamura, T, Hosoya, T, Yamaguchi, Y, Hano, H (2004) A case of renal sarcoidosis: a special reference to calcium metabolism as a diagnostic and the therapeutic implications. Clin Exp Nephrol 8: pp. 375-379 CrossRef
77. Mocan, H, Yildiran, A, Camlibel, T, Kuzey, GM (2000) Microscopic nephrocalcinosis and hypercalciuria in nephrotic syndrome. Hum Pathol 31: pp. 1363-1367 CrossRef
78. Praga, M, Mart铆nez, MA, Andr茅s, A, Alegre, R, Vara, J, Morales, E, Herrero, JC, Novo, O, Rodicio, JL (1998) Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Kidney Int 54: pp. 915-920 CrossRef
79. Szeto, CC, Chow, KM (2005) Nephrotoxicity related to new therapeutic compounds. Ren Fail 27: pp. 329-333 CrossRef
80. Yarlagadda, SG, Perazella, MA (2008) Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf 7: pp. 147-158 CrossRef
81. Daudon, M, Jungers, P (2004) Drug-induced renal calculi: epidemiology, prevention and management. Drugs 64: pp. 245-275 CrossRef
82. Perazella, MA (1999) Crystal-induced acute renal failure. Am J Med 106: pp. 459-465 CrossRef
83. Davidson, MB, Thakkar, S, Hix, JK, Bhandarkar, ND, Wong, A, Schreiber, MJ (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116: pp. 646-654 CrossRef
84. Kang, JS, Lee, MH (2009) Overview of therapeutic drug monitoring. Korean J Intern Med 24: pp. 1-10 24.1.1" target="_blank" title="It opens in new window">CrossRef
85. Golubnitschaja, O, Kinkorova, J, Costigliola, V (2014) Predictive, preventive and personalised medicine as the hardcore of 鈥楬orizon 2020鈥? EPMA position paper. EPMA J 5: pp. 6 CrossRef - 刊物主题：Biomedicine general; Medicine/Public Health, general;
- 出版者：BioMed Central
- ISSN：1878-5085
文摘
Crystal formation reflects the entire composition of the surrounding solution. In case of urolithiasis, induced crystal formation in native urine has led to the development of the Bonn-Risk-Index (BRI), a valuable tool to quantify an individual's risk of calcium oxalate urolithiasis. If the progression of a disease is associated with characteristic changes in the activities of urinary components, this leads to an altered urinary crystallisation capacity. Therefore, the results of induced urinary crystal formation can be used to detect and monitor any disease linked to the altered urinary composition. Since crystal formation inherently takes into account the entire urinary composition, the influence of the disease on individual urinary parameters does not have to be known in order to monitor the consequent pathologic alterations. In this paper, we review the background of urinary crystal formation analysis and describe its established application in urolithiasis monitoring as well as potential further fields of clinical application.